1964 related articles for article (PubMed ID: 8219762)
1. Modulation by MHC class I antigens of the biology of melanoma cells. Non-immunological mechanisms.
Gattoni-Celli S; Calorini L; Simile MM; Ferrone S
Melanoma Res; 1993 Aug; 3(4):285-9. PubMed ID: 8219762
[TBL] [Abstract][Full Text] [Related]
2. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.
Algarra I; García-Lora A; Cabrera T; Ruiz-Cabello F; Garrido F
Cancer Immunol Immunother; 2004 Oct; 53(10):904-10. PubMed ID: 15069585
[TBL] [Abstract][Full Text] [Related]
3. MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells.
Garrido C; Paco L; Romero I; Berruguilla E; Stefansky J; Collado A; Algarra I; Garrido F; Garcia-Lora AM
Carcinogenesis; 2012 Mar; 33(3):687-93. PubMed ID: 22219178
[TBL] [Abstract][Full Text] [Related]
4. S100A4 expression with reduced E-cadherin expression predicts distant metastasis of human malignant melanoma cell lines in the NOD/SCID/gammaCnull (NOG) mouse model.
Ikoma N; Yamazaki H; Abe Y; Oida Y; Ohnishi Y; Suemizu H; Matsumoto H; Matsuyama T; Ohta Y; Ozawa A; Ueyama Y; Nakamura M
Oncol Rep; 2005 Sep; 14(3):633-7. PubMed ID: 16077966
[TBL] [Abstract][Full Text] [Related]
5. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
Chen PW; Ananthaswamy HN
J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
[TBL] [Abstract][Full Text] [Related]
6. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
[TBL] [Abstract][Full Text] [Related]
7. Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity.
Garrido C; Algarra I; Maleno I; Stefanski J; Collado A; Garrido F; Garcia-Lora AM
Cancer Immunol Immunother; 2010 Jan; 59(1):13-26. PubMed ID: 19430787
[TBL] [Abstract][Full Text] [Related]
8. MHC class I antigens, immune surveillance, and tumor immune escape.
Garcia-Lora A; Algarra I; Garrido F
J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
[TBL] [Abstract][Full Text] [Related]
9. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2 augmented activation of tumor associated macrophage plays the main role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro.
Ouyang GF; Saio M; Suwa T; Imai H; Nakagawa J; Nonaka K; Umemura N; Kijima M; Takami T
Int J Oncol; 2006 May; 28(5):1201-8. PubMed ID: 16596236
[TBL] [Abstract][Full Text] [Related]
11. Autophagy facilitates major histocompatibility complex class I expression induced by IFN-γ in B16 melanoma cells.
Li B; Lei Z; Lichty BD; Li D; Zhang GM; Feng ZH; Wan Y; Huang B
Cancer Immunol Immunother; 2010 Feb; 59(2):313-21. PubMed ID: 19680649
[TBL] [Abstract][Full Text] [Related]
12. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
[TBL] [Abstract][Full Text] [Related]
13. A demonstration of a strain related restriction effect in the formation of experimental metastases.
Jack AS; McVeigh KL
J Pathol; 1987 May; 152(1):37-45. PubMed ID: 3625393
[TBL] [Abstract][Full Text] [Related]
14. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes.
Seliger B; Harders C; Wollscheid U; Staege MS; Reske-Kunz AB; Huber C
Exp Hematol; 1996 Sep; 24(11):1275-9. PubMed ID: 8862437
[TBL] [Abstract][Full Text] [Related]
15. High levels of Fas ligand and MHC class II in the absence of CD80 or CD86 expression and a decreased CD4+ T cell Infiltration, enables murine skin tumours to progress.
Byrne SN; Halliday GM
Cancer Immunol Immunother; 2003 Jun; 52(6):396-402. PubMed ID: 12739069
[TBL] [Abstract][Full Text] [Related]
16. Tumour MHC class I downregulation and immunotherapy (Review).
Bubeník J
Oncol Rep; 2003; 10(6):2005-8. PubMed ID: 14534734
[TBL] [Abstract][Full Text] [Related]
17. Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL.
Bakker AB; Phillips JH; Figdor CG; Lanier LL
J Immunol; 1998 Jun; 160(11):5239-45. PubMed ID: 9605119
[TBL] [Abstract][Full Text] [Related]
18. Attenuation of the Fas-L independent B16BL6 melanoma lymphocidic capacity by H-2K class I molecules.
Kellman-Pressman S; Fishman D; Tsory S; Segal S
Immunol Lett; 2005 Sep; 100(2):146-52. PubMed ID: 15935480
[TBL] [Abstract][Full Text] [Related]
19. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.
Engelhard VH; Bullock TN; Colella TA; Mullins DW
Cancer J; 2000 May; 6 Suppl 3():S272-80. PubMed ID: 10874498
[TBL] [Abstract][Full Text] [Related]
20. Influence on metastasis of the reduction of major histocompatibility complex (MHC) class I gene with an antisense oligonucleotide.
Kanbe M; Arita D; Satoh T; Yokoyama A; Murakawa Y; Kikuchi H; Kanamaru R
Anticancer Drug Des; 1992 Aug; 7(4):341-50. PubMed ID: 1510801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
